Mesenchymal Stem Cells Ameliorate Adriamycin Induced Proteinuric Nephropathy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose:Glomerulonephropathy (GN) often manifests as proteinuria and progresses to chronic renal failure without specific therapy. Mesenchymal stem cell (MSC) has been tried as a therapeutic agent in experimental GN, and previous studies showed that administration of MSC concomitantly to the insult inducing GN or via intra-renal administration ameliorated proteinuria. The purpose of this study was to test the therapeutic potential of MSC administered via intravenous route at the time of clinically evident proteinuria. Methods:MSCs were administered intravenously via tail vain into the mice with adriamycin (ADR) induced nephropathy (ADR-GN), two weeks after ADR injection when massive proteinuria was evident. To test the capacity of MSC modulate the cytokine production in the inflammatory milieu, the concentrations of IFN-γ and IL-10 were measured in the supernatant of in vitro mixed lymphocyte culture (MLC) with or without additional MSC. Results:MSCs administered intravenously into the proteinuric mice with ADR-GN accelerated the recovery of this experimental GN with disappearance of proteinuria in two weeks when the saline treated (control) mice still showed significant proteinuria. The mice treated with MSC also had a tendency of better survival. Addition of MSC decreased IFN-γ and increased IL-10 in the supernatant of MLC. Discussion:This study showed that MSC had a therapeutic potential even when administered in a more clinically relevant setting into a proteinuric glomerulonephropathy model. Further study to verify the mechanism and long-term safety of this phenomenon is required.
Abstract
Purpose:Glomerulonephropathy (GN) often manifests as proteinuria and progresses to chronic renal failure without specific therapy. Mesenchymal stem cell (MSC) has been tried as a therapeutic agent in experimental GN, and previous studies showed that administration of MSC concomitantly to the insult inducing GN or via intra-renal administration ameliorated proteinuria. The purpose of this study was to test the therapeutic potential of MSC administered via intravenous route at the time of clinically evident proteinuria. Methods:MSCs were administered intravenously via tail vain into the mice with adriamycin (ADR) induced nephropathy (ADR-GN), two weeks after ADR injection when massive proteinuria was evident. To test the capacity of MSC modulate the cytokine production in the inflammatory milieu, the concentrations of IFN-γ and IL-10 were measured in the supernatant of in vitro mixed lymphocyte culture (MLC) with or without additional MSC. Results:MSCs administered intravenously into the proteinuric mice with ADR-GN accelerated the recovery of this experimental GN with disappearance of proteinuria in two weeks when the saline treated (control) mice still showed significant proteinuria. The mice treated with MSC also had a tendency of better survival. Addition of MSC decreased IFN-γ and increased IL-10 in the supernatant of MLC. Discussion:This study showed that MSC had a therapeutic potential even when administered in a more clinically relevant setting into a proteinuric glomerulonephropathy model. Further study to verify the mechanism and long-term safety of this phenomenon is required.
참고문헌 (26)
- Eddy AA, "Interstitial nephritis induced by protein-overload proteinuria", Am J Pathol, 135, pp.719~733 (1989)
- Remuzzi G, "Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes", J Clin Invest, 116, pp.288~296 (2006)
- Mangi AA, "Mesenchymal stem cells modified with akt prevent remodeling and restore performance of infarcted hearts", Nat Med, 9, pp.1195~1201 (2003)
- Barbash IM, "Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: Feasibility, cell migration, and body distribution", Circulation, 108, pp.863~868 (2003)
- Aggarwal S, "Human mesenchymal stem cells modulate allogeneic immune cell responses", Blood, 105, pp.1815~1822 (2005)
- Beyth S, "Human mesenchymal stem cells alter antigen-presenting cell maturation and induce t-cell unresponsiveness", Blood, 105, pp.2214~2219 (2005)
- Frank MH, "Immunomodulatory functions of mesenchymal stem cells", Lancet, 363, pp.1411~1412 (2004)
- Le Blanc K, "Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase ii study", Lancet, 371, pp.1579~1586 (2008)
- Togel F, "Autologous and allogeneic marrow stromal cells are safe and effective for the treatment of acute kidney injury", Stem Cells Dev, 18, pp.475~485 (2009)
- Togel F, "Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation- independent mechanisms", Am J Physiol Renal Physiol, 289, pp.F31~42 (2005)
- Herrera MB, "Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury", Int J Mol Med, 14, pp.1035~1041 (2004)
- Kunter U, "Transplanted mesenchymal stem cells accelerate glomerular healing in experimental glomerulonephritis", J Am Soc Nephrol, 17, pp.2202~2212 (2006)
- Kunter U, "Mesenchymal stem cells prevent progressive experimental renal failure but maldifferentiate into glomerular adipocytes", J Am Soc Nephrol, 18, pp.1754~1764 (2007)
- Magnasco A, "Mesenchymal stem cells protective effect in adriamycin model of nephropathy", Cell Transplant, 17, pp.1157~1167 (2008)
- Wang Y, "Partial depletion of macrophages by ed7 reduces renal injury in adriamycin nephropathy", Nephrology (Carlton), 10, pp.470~477 (2005)
- Wang Y, "Depletion of cd4(+) t cells aggravates glomerular and interstitial injury in murine adriamycin nephropathy", Kidney Int, 59, pp.975~984 (2001)
- Rangan GK, "Cytokine gene expression in adriamycin nephropathy: Effects of antioxidant nuclear factor kappab inhibitors in established disease", Nephron, 86, pp.482~490 (2000)
- Morigi M, "The regenerative potential of stem cells in acute renal failure", Cell Transplant, 15(1), pp.S111~117 (2006)
- Peister A, "Adult stem cells from bone marrow (mscs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential", Blood, pp.1662~1668 (2004)
- Wells AD, "Following the fate of individual t cells throughout activation and clonal expansion. Signals from t cell receptor and cd28 differentially regulate the induction and duration of a proliferative response", J Clin Invest, 100, pp.3173~3183 (1997)
- Okuda S, "Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix", J Clin Invest, 86, pp.453~462 (1990)
- Degauque N, "Immunostimulatory tim-1-specific antibody deprograms tregs and prevents transplant tolerance in mice", J Clin Invest, 118, pp.735~741 (2008)
- Fischer UM, "Pulmonary passage is a major obstacle for intravenous stem cell delivery: The pulmonary first-pass effect", Stem Cells Dev, 18, pp.683~692 (2009)
- Gao J, "The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion", Cells Tissues Organs, 169, pp.12~20 (2001)
- Ninichuk V, "Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen 4a3-deficient mice", Kidney Int, 70, pp.121~129 (2006)
- Togel F, "Bioluminescence imaging to monitor the in vivo distribution of administered mesenchymal stem cells in acute kidney injury", Am J Physiol Renal Physiol, 295, pp.F315~321 (2008)